118 related articles for article (PubMed ID: 38586956)
21. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease.
Alexander EK; Larsen PR
J Clin Endocrinol Metab; 2002 Mar; 87(3):1073-7. PubMed ID: 11889166
[TBL] [Abstract][Full Text] [Related]
22. Evidence for higher success rates and successful treatment earlier in Graves' disease with higher radioactive iodine doses.
Sztal-Mazer S; Nakatani VY; Bortolini LG; Boguszewski CL; Graf H; de Carvalho GA
Thyroid; 2012 Oct; 22(10):991-5. PubMed ID: 22953990
[TBL] [Abstract][Full Text] [Related]
23. Hypothyroidism after iodine-131 or surgical therapy for Graves' disease hyperthyroidism.
Gómez JM; Gómez N; Amat M; Biondo S; Rafecas A; Jaurrieta E; Soler J
Ann Endocrinol (Paris); 2000 Sep; 61(3):184-91. PubMed ID: 10970941
[TBL] [Abstract][Full Text] [Related]
24. Clinical course of pediatric and adolescent Graves' disease treated with radioactive iodine.
Pinto T; Cummings EA; Barnes D; Salisbury S
J Pediatr Endocrinol Metab; 2007 Sep; 20(9):973-80. PubMed ID: 18038706
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness and Safety of Radioactive Iodine Therapy in Childhood Graves’ Disease in Khon Kaen, Thailand.
Getsuwan S; Wiromrat P; Panamonta O; Panamonta M; Paireepinas S
J Med Assoc Thai; 2016 Aug; 99 Suppl 5():S112-9. PubMed ID: 29905996
[TBL] [Abstract][Full Text] [Related]
26. A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis.
Bhakat B; Pal J; Das S; Charaborty SK; SircarMedical NR; Kolkata ; RGKar ; NorthBengal ; Siliguri
J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116030
[TBL] [Abstract][Full Text] [Related]
27. Radioiodine treatment outcomes in thyroid glands previously irradiated for Graves' hyperthyroidism.
Leslie WD; Peterdy AE; Dupont JO
J Nucl Med; 1998 Apr; 39(4):712-6. PubMed ID: 9544686
[TBL] [Abstract][Full Text] [Related]
28. Objective estimates of the probability of developing hypothyroidism following radioactive iodine treatment of thyrotoxicosis.
Ahmad AM; Ahmad M; Young ET
Eur J Endocrinol; 2002 Jun; 146(6):767-75. PubMed ID: 12039696
[TBL] [Abstract][Full Text] [Related]
29. Radioactive iodine treatment for Graves' hyperthyroidism: incidence of Graves orbitopathy.
Quah NQX; Sobti MM; Wren AM; Scawn R; Kalogianni E; Cleland J; Maenhout A
Nucl Med Commun; 2024 Feb; 45(2):103-107. PubMed ID: 37982569
[TBL] [Abstract][Full Text] [Related]
30. Influence of Short-Term Dietary and Therapeutic Iodine Restriction on the Therapeutic Effects of Radioactive Iodine Therapy in Patients with Graves' Disease.
Nishio R; Uchida T; Suzuki L; Onose H; Goto H; Yamada E; Satoh H; Watada H
Thyroid; 2021 Mar; 31(3):439-445. PubMed ID: 32729394
[No Abstract] [Full Text] [Related]
31. Transient hypothyroidism after iodine-131 treatment of Graves' disease.
Gómez JM; Virgili N; Soler J; Fernández M; Montaña E
Thyroidology; 1989 Dec; 1(3):149-52. PubMed ID: 2484879
[TBL] [Abstract][Full Text] [Related]
32. Changes in thyroid volume in response to radioactive iodine for Graves' hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome.
Murakami Y; Takamatsu J; Sakane S; Kuma K; Ohsawa N
J Clin Endocrinol Metab; 1996 Sep; 81(9):3257-60. PubMed ID: 8784079
[TBL] [Abstract][Full Text] [Related]
33. Predictive value of pyramidal lobe, percentage thyroid uptake and age for ablation outcome after 15 mCi fixed dose of radioiodine-131 in Graves' disease.
Zaman MU; Fatima N; Zaman U; Sajjad Z; Zaman A; Tahseen R
Indian J Nucl Med; 2015; 30(4):309-13. PubMed ID: 26430313
[TBL] [Abstract][Full Text] [Related]
34. Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal.
Bogazzi F; Giovannetti C; Fessehatsion R; Tanda ML; Campomori A; Compri E; Rossi G; Ceccarelli C; Vitti P; Pinchera A; Bartalena L; Martino E
J Clin Endocrinol Metab; 2010 Jan; 95(1):201-8. PubMed ID: 19906789
[TBL] [Abstract][Full Text] [Related]
35. Prevention of Orbitopathy by Oral or Intravenous Steroid Prophylaxis in Short Duration Graves' Disease Patients Undergoing Radioiodine Ablation: A Prospective Randomized Control Trial Study.
Vannucchi G; Covelli D; Campi I; Currò N; Dazzi D; Rodari M; Pepe G; Chiti A; Guastella C; Lazzaroni E; Salvi M
Thyroid; 2019 Dec; 29(12):1828-1833. PubMed ID: 31860407
[No Abstract] [Full Text] [Related]
36. Correlation between thyroid volume and humoral thyroid autoimmunity after radioiodine therapy in Graves' disease.
Sawicka N; Sowiński J
Endokrynol Pol; 2012; 63(1):10-3. PubMed ID: 22378091
[TBL] [Abstract][Full Text] [Related]
37. Time course to hypothyroidism after fixed-dose radioablation therapy of Graves' disease in children.
Nebesio TD; Siddiqui AR; Pescovitz OH; Eugster EA
J Pediatr; 2002 Jul; 141(1):99-103. PubMed ID: 12091858
[TBL] [Abstract][Full Text] [Related]
38. Radioiodine treatment of hyperthyroidism: prognostic factors affecting outcome.
Erem C; Kandemir N; Hacihasanoglu A; Ersöz HO; Ukinc K; Kocak M
Endocrine; 2004 Oct; 25(1):55-60. PubMed ID: 15545707
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factor analysis in 325 patients with Graves' disease treated with radioiodine therapy.
Yang D; Xue J; Ma W; Liu F; Fan Y; Rong J; Yang A; Yu Y
Nucl Med Commun; 2018 Jan; 39(1):16-21. PubMed ID: 29040161
[TBL] [Abstract][Full Text] [Related]
40. Radioactive Iodine: A Living History.
Daniels GH; Ross DS
Thyroid; 2023 Jun; 33(6):666-673. PubMed ID: 37307104
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]